The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation

Figure 3

KJS018A inhibits metastatic traits in hepatic malignant cells. (a) Migration assay of SNU398 and HepG2 in presence of 50 μg/mL KJS018A with or without 100 ng/mL PMA activation. (b) Invasion assay of SNU398 and HepG2 in presence of 50 μg/mL KJS018A with or without 100 ng/mL PMA activation. (c) Wound healing assay of SNU398 and HepG2 treated with 50 μg/mL KJS018A with or without 100 ng/mL PMA activation. (d) EMT markers in lysates of SNU398 and HepG2 after 24 h exposed with 50 μg/mL KJS018A treatment. P< 0.05; P< 0.0001. Scale bar, 50 μm. The experiment was repeated 3 times.

(a)

(b)

(c)

(d)